Metaphorebio
52 employees on LinkedIn · 2 known investors
Find your way into Metaphorebio
Sign up to see every warm intro you have to Metaphorebio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Metaphorebio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Metaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action. The company aims to create antibodies that activate pathways, modulate signaling, and engage multiple targets to treat complex diseases.
Investors · 2
Related companies · 2
Fore BiotherapeuticsFore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program. It runs clinical trials such as the Forte Trial and offers expanded access programs for patients.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Metaphorebio.
Frequently asked questions
- What does Metaphorebio do?
- Metaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action. The company aims to create antibodies that activate pathways, modulate signaling, and engage multiple targets to treat complex diseases.
- Who are Metaphorebio's investors?
- Metaphorebio's investors include Flagship Pioneering, Global Brain.



